Pediatric Oncology | Specialty

The OncLive Pediatric Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of cancers in pediatric patients, including acute lymphoblastic leukemia, acute myeloid leukemia, brain cancers, sarcomas, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in childhood and adolescent and young adult cancers.

Dr. Wistinghausen Discusses Targeted Therapies for Pediatric NHL

May 31st 2018

Birte Wistinghausen, MD, associate professor, Pediatrics, medical director of the Division of Pediatric Hematology-Oncology, the Kravis Children's Hospital and Icahn School of Medicine at Mount Sinai, discusses targeted therapies for the treatment of pediatric patients with non-Hodgkin lymphoma.

FDA Grants Frontline Eltrombopag Priority Review for Severe Aplastic Anemia

May 31st 2018

The FDA has granted a priority review to a supplemental new drug application for eltrombopag (Promacta) for use in combination with standard immunosuppressive therapy as a frontline treatment for patients with severe aplastic anemia.

Lead Investigator Discusses Tazemetostat Data in INI1-Negative Pediatric Tumors

May 30th 2018

Susan N. Chi, MD, discusses the rationale for using tazemetostat in pediatric patients with INI1-negative rhabdoid tumors, as well as the future steps being taken with this treatment.

FDA Grants Crizotinib Breakthrough Designation for MET+ NSCLC and ALK+ ALCL

May 30th 2018

The FDA has granted crizotinib a breakthrough therapy designation for the treatment of patients with metastatic non–small cell lung cancer with MET exon 14 alterations, and for use in patients with relapsed/refractory ALK+ anaplastic large cell lymphoma.

Dr. Fraizer Discusses the MaGIC Consortium

May 29th 2018

Lindsay Frazier, MD, institute physician, Pediatric Hematology/Oncology, Dana-Farber Cancer Institute, associate professor of pediatrics, Harvard Medical School, discusses the Malignant Germ Cell International Consortium (MaGIC) in pediatric and rare tumors.

FDA Grants Larotrectinib Priority Review for NTRK+ Cancers

May 29th 2018

The FDA has granted a priority review to a new drug application for larotrectinib for the treatment of adult and pediatric patients with locally advanced or metastatic solid tumors with an NTRK gene fusion.

COG Addresses Unmet Needs in Pediatric NHL

May 25th 2018

Birte Wistinghausen, MD, shares her insight on the potential for targeted therapies in the treatment of pediatric non-Hodgkin lymphoma, and the steps that the Children’s Oncology Group is taking to cure all patients with this disease.

Study Identifies Factors Linked to Long-Term Survival in Pediatric/Adolescent DIPG

May 24th 2018

A number of biological factors, including age at diagnosis, symptom duration at diagnosis, and HIST1H3B mutation status, are associated with survival ≥2 years in children and young adults with diffuse intrinsic pontine glioma, a brainstem malignancy with a median survival

Autoimmune Disease May Have Complicated Treatment for Pediatric ITP

May 23rd 2018

An underlying autoimmune condition may have played a role in making a 13-year-old patient refractory to treatment for immune thrombocytopenia.

Ponatinib Shows Promise in Pediatric/Adolescent ALL Patients

May 23rd 2018

Ponatinib (Iclusig) induced a complete remission in one pediatric/adolescent patient with Philadelphia chromosome-positive acute lymphoblastic leukemia, and demonstrated promising clinical activity in another.

Tocilizumab Resolves CRS in Pediatric B-ALL Without Reducing Tisagenlecleucel Efficacy

May 22nd 2018

Tocilizumab resolved cytokine release syndrome in patients with relapsed/refractory pediatric B-cell acute lymphoblastic leukemia without reducing the efficacy of tisagenlecleucel.

Dr. Baker on the Importance of Symptom Management in Children With Cancer

May 22nd 2018

Justin N. Baker, MD, chief, Division of Quality of Life and Palliative Care, attending physician, Quality of Life Service, St. Jude Children’s Research Hospital, discusses the importance of symptom management in children with cancer.

Larotrectinib Inches Closer to FDA Approval for TRK+ Cancers

May 21st 2018

Anna Farago, MD, PhD, discusses the biology of larotrectinib, as well as the importance of genetic testing for molecular alterations like TRK in patients with locally advanced solid tumors.

Dr. Geller on Renal Rhabdoid Tumors in Pediatric Patients

May 17th 2018

James I. Geller, MD, medical director, Kidney and Liver Tumors Program, Cincinnati Children’s Hospital Medical Center, discusses renal rhabdoid tumors in pediatric patients.

Nelarabine Boosts 4-Year DFS Above 90% in Pediatric/AYA T-Cell Cancers

May 17th 2018

Adding nelarabine to escalating-dose methotrexate induced a 4-year disease-free survival rate of 91% in a cohort of pediatric and young adult patients with newly diagnosed T-cell cancers.

Dr. Patterson Discusses Concerns With TKIs in Children With CML

May 15th 2018

Briana Patterson, MD, assistant professor, Division of Endocrinology, Aflac Cancer Center, Department of Pediatrics, Emory University School of Medicine, discusses concerns regarding the use of tyrosine kinase inhibitors in the treatment of children with chronic myeloid leukemia.

Expert Explains State of TKI Treatment in Pediatric CML

May 10th 2018

Discontinuation of tyrosine kinase inhibitor treatment may be a possibility for children with chronic myeloid leukemia and, because they could be on-treatment for decades, treatment-free remission is even more important for pediatric patients than for adults.

Dr. Wistinghausen Discusses the Treatment of Pediatric NHL

May 9th 2018

Birte Wistinghausen, MD, medical director of the Division of Pediatric Hematology-Oncology, the Kravis Children's Hospital and Icahn School of Medicine at Mount Sinai, discusses the treatment of pediatric patients with non-Hodgkin lymphoma.

Eltrombopag Improves Platelet Count in Pediatric HIV

May 8th 2018

Eltrombopag (Promacta) boosted the platelet count in a 13-year-old boy with HIV-associated thrombocytopenia, according to case study results presented at the 2018 American Society of Pediatric Hematology/Oncology Conference.

Dr. Engel on the Use of Eltrombopag in HIV-Related Thrombocytopenia

May 5th 2018

Elissa Engel, MD, pediatric resident, University of South Florida, discusses the successful use of eltrombopag (Promacta) in a pediatric patient with HIV-related thrombocytopenia.